These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 38160359)

  • 1. Type 2 Diabetes Moderates the Association Between Amyloid and 1-Year Change in Everyday Functioning in Older Veterans.
    Alshaheri Durazo A; Weigand AJ; Bangen KJ; Membreno R; Mudaliar S; Thomas KR;
    J Alzheimers Dis; 2024; 97(1):219-228. PubMed ID: 38160359
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cognition and Amyloid-β in Older Veterans: Characterization and Longitudinal Outcomes of Data-Derived Phenotypes.
    Thomas KR; Clark AL; Weigand AJ; Edwards L; Durazo AA; Membreno R; Luu B; Rantins P; Ly MT; Rotblatt LJ; Bangen KJ; Jak AJ;
    J Alzheimers Dis; 2024; 99(1):417-427. PubMed ID: 38669550
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regional cerebral tau predicts decline in everyday functioning across the Alzheimer's disease spectrum.
    Dubbelman MA; Mimmack KJ; Sprague EH; Amariglio RE; Vannini P; Marshall GA;
    Alzheimers Res Ther; 2023 Jul; 15(1):120. PubMed ID: 37408004
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma Glial Fibrillary Acidic Protein Levels Differ Along the Spectra of Amyloid Burden and Clinical Disease Stage.
    Asken BM; Elahi FM; La Joie R; Strom A; Staffaroni AM; Lindbergh CA; Apple AC; You M; Weiner-Light S; Brathaban N; Fernandes N; Karydas A; Wang P; Rojas JC; Boxer AL; Miller BL; Rabinovici GD; Kramer JH; Casaletto KB
    J Alzheimers Dis; 2020; 78(1):265-276. PubMed ID: 32986672
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PTSD moderates the association between subjective cognitive decline and Alzheimer's disease biomarkers in older veterans.
    Luu B; Bangen KJ; Clark AL; Weigand AJ; Rantins P; Garcia ME; Urias U; Merritt VC; Thomas KR;
    Aging Ment Health; 2024 Aug; ():1-9. PubMed ID: 39118434
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study.
    Doraiswamy PM; Sperling RA; Coleman RE; Johnson KA; Reiman EM; Davis MD; Grundman M; Sabbagh MN; Sadowsky CH; Fleisher AS; Carpenter A; Clark CM; Joshi AD; Mintun MA; Skovronsky DM; Pontecorvo MJ;
    Neurology; 2012 Oct; 79(16):1636-44. PubMed ID: 22786606
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Traumatic brain injury fast-forwards Alzheimer's pathology: evidence from amyloid positron emission tomorgraphy imaging.
    Mohamed AZ; Nestor PJ; Cumming P; Nasrallah FA;
    J Neurol; 2022 Feb; 269(2):873-884. PubMed ID: 34191080
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease: A Head-to-Head Comparison Against Amyloid Positron Emission Tomography and Magnetic Resonance Imaging.
    Ossenkoppele R; Smith R; Mattsson-Carlgren N; Groot C; Leuzy A; Strandberg O; Palmqvist S; Olsson T; Jögi J; Stormrud E; Cho H; Ryu YH; Choi JY; Boxer AL; Gorno-Tempini ML; Miller BL; Soleimani-Meigooni D; Iaccarino L; La Joie R; Baker S; Borroni E; Klein G; Pontecorvo MJ; Devous MD; Jagust WJ; Lyoo CH; Rabinovici GD; Hansson O
    JAMA Neurol; 2021 Aug; 78(8):961-971. PubMed ID: 34180956
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Impact of Amyloid-β or Tau on Cognitive Change in the Presence of Severe Cerebrovascular Disease.
    Jang H; Kim HJ; Choe YS; Kim SJ; Park S; Kim Y; Kim KW; Lyoo CH; Cho H; Ryu YH; Choi JY; DeCarli C; Na DL; Seo SW;
    J Alzheimers Dis; 2020; 78(2):573-585. PubMed ID: 33016911
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impaired cerebral blood flow in type 2 diabetes mellitus - A comparative study with subjective cognitive decline, vascular dementia and Alzheimer's disease subjects.
    Chau ACM; Cheung EYW; Chan KH; Chow WS; Shea YF; Chiu PKC; Mak HKF
    Neuroimage Clin; 2020; 27():102302. PubMed ID: 32521474
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Region-Specific Association of Subjective Cognitive Decline With Tauopathy Independent of Global β-Amyloid Burden.
    Buckley RF; Hanseeuw B; Schultz AP; Vannini P; Aghjayan SL; Properzi MJ; Jackson JD; Mormino EC; Rentz DM; Sperling RA; Johnson KA; Amariglio RE
    JAMA Neurol; 2017 Dec; 74(12):1455-1463. PubMed ID: 28973551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interactive versus additive relationships between regional cortical thinning and amyloid burden in predicting clinical decline in mild AD and MCI individuals.
    d'Oleire Uquillas F; Jacobs HIL; Hanseeuw B; Marshall GA; Properzi M; Schultz AP; LaPoint MR; Johnson KA; Sperling RA; Vannini P
    Neuroimage Clin; 2018; 17():388-396. PubMed ID: 29159051
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of the Informant-Reported Memory Decline With Cognitive and Brain Deterioration Through the Alzheimer Clinical Continuum.
    Kuhn E; Perrotin A; La Joie R; Touron E; Dautricourt S; Vanhoutte M; Vivien D; de La Sayette V; Chételat G;
    Neurology; 2023 Jun; 100(24):e2454-e2465. PubMed ID: 37085328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Left lateralized cerebral glucose metabolism declines in amyloid-β positive persons with mild cognitive impairment.
    Weise CM; Chen K; Chen Y; Kuang X; Savage CR; Reiman EM;
    Neuroimage Clin; 2018; 20():286-296. PubMed ID: 30101060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combining tau-PET and fMRI meta-analyses for patient-centered prediction of cognitive decline in Alzheimer's disease.
    Biel D; Luan Y; Brendel M; Hager P; Dewenter A; Moscoso A; Otero Svaldi D; Higgins IA; Pontecorvo M; Römer S; Steward A; Rubinski A; Zheng L; Schöll M; Shcherbinin S; Ewers M; Franzmeier N;
    Alzheimers Res Ther; 2022 Nov; 14(1):166. PubMed ID: 36345046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regional Hypoperfusion Predicts Decline in Everyday Functioning at Three-Year Follow-Up in Older Adults without Dementia.
    Sanchez DL; Thomas KR; Edmonds EC; Bondi MW; Bangen KJ;
    J Alzheimers Dis; 2020; 77(3):1291-1304. PubMed ID: 32831202
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Type 2 diabetes mellitus and biomarkers of neurodegeneration.
    Moran C; Beare R; Phan TG; Bruce DG; Callisaya ML; Srikanth V;
    Neurology; 2015 Sep; 85(13):1123-30. PubMed ID: 26333802
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Basal forebrain atrophy correlates with amyloid β burden in Alzheimer's disease.
    Kerbler GM; Fripp J; Rowe CC; Villemagne VL; Salvado O; Rose S; Coulson EJ;
    Neuroimage Clin; 2015; 7():105-13. PubMed ID: 25610772
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer's disease (BLAZE).
    Salloway S; Honigberg LA; Cho W; Ward M; Friesenhahn M; Brunstein F; Quartino A; Clayton D; Mortensen D; Bittner T; Ho C; Rabe C; Schauer SP; Wildsmith KR; Fuji RN; Suliman S; Reiman EM; Chen K; Paul R
    Alzheimers Res Ther; 2018 Sep; 10(1):96. PubMed ID: 30231896
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The combination of apolipoprotein E4, age and Alzheimer's Disease Assessment Scale - Cognitive Subscale improves the prediction of amyloid positron emission tomography status in clinically diagnosed mild cognitive impairment.
    Ba M; Ng KP; Gao X; Kong M; Guan L; Yu L;
    Eur J Neurol; 2019 May; 26(5):733-e53. PubMed ID: 30561868
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.